Cheng-Hua Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cheng-Hua Jin has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
Chuang Liu
9 shared publicationsFang-Yan Guo
College of Pharmacy, Yanbian University
6 shared publications- Li-Hua Lian
Key Laboratory of Traditional Chinese Korean Medicine Research of State Ethnic Affairs Commission, College of Pharmacy, Yanbian University, Yanji, Jilin Province, 133002, China; Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, Jilin Province, 133002, China
6 shared publications Siqi Li
6 shared publicationsChanghao Zhang
Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China
5 shared publicationsHu-Ri Piao
Key Laboratory of Natural Medicines of the Changbai Mountain Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China
5 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1853424
Editorial: The molecular mechanisms and therapeutic implications of protein kinase inhibitors in cancer therapy
In the six sample analyses of clinical patients using protein kinase inhibitors covered in this research topic, it can be seen that the use of targeted protein kinase inhibitors improves the efficacy and safety of clinical treatment, providing more treatment options.Li et al. reported the first case of rhabdomyosarcoma patient carrying positive BCR-ABL1 fusion gene discovered at Shanghai Children's Medical Center. In addition to traditional tumor treatment methods such as chemotherapy, surgery, and radiotherapy, tyrosine kinase inhibitors (TKIs) were used in combination, resulting in early complete remission (CR) for the patient. TKIs competitively inhibit ATP binding sites of BCR-ABL1 oncogenic protein, thereby suppressing protein phosphorylation involved in cellular signaling transduction. For patients diagnosed with high-risk, refractory, recurrent, and drug-resistant malignant solid tumors, conducting genomic analysis to identify therapeutic targets and using kinase inhibitors for targeted therapy may provide additional treatment options for cancer patients. Chronic myeloid leukemia (CML) is a severe and well-studied hematological malignancy, abnormally activated tyrosine Collectively, these studies establish kinase signaling as a unifying framework connecting cell death, immunity, oncogenic fusion, and cell cycle control. From ICD modulation and immune evasion to biomarker-guided therapy and pediatric cancer targeting, this body of work accelerates the development of isoform-selective inhibitors, rational combinations, and broad genomic screening. Moving forward, integrating kinase profiling with immune monitoring will further refine precision oncology, expanding durable benefit across diverse tumor types.
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1853424
Open AccessEditorial: The molecular mechanisms and therapeutic implications of protein kinase inhibitors in cancer therapy
In the six sample analyses of clinical patients using protein kinase inhibitors covered in this research topic, it can be seen that the use of targeted protein kinase inhibitors improves the efficacy and safety of clinical treatment, providing more treatment options.Li et al. reported the first case of rhabdomyosarcoma patient carrying positive BCR-ABL1 fusion gene discovered at Shanghai Children's Medical Center. In addition to traditional tumor treatment methods such as chemotherapy, surgery, and radiotherapy, tyrosine kinase inhibitors (TKIs) were used in combination, resulting in early complete remission (CR) for the patient. TKIs competitively inhibit ATP binding sites of BCR-ABL1 oncogenic protein, thereby suppressing protein phosphorylation involved in cellular signaling transduction. For patients diagnosed with high-risk, refractory, recurrent, and drug-resistant malignant solid tumors, conducting genomic analysis to identify therapeutic targets and using kinase inhibitors for targeted therapy may provide additional treatment options for cancer patients. Chronic myeloid leukemia (CML) is a severe and well-studied hematological malignancy, abnormally activated tyrosine Collectively, these studies establish kinase signaling as a unifying framework connecting cell death, immunity, oncogenic fusion, and cell cycle control. From ICD modulation and immune evasion to biomarker-guided therapy and pediatric cancer targeting, this body of work accelerates the development of isoform-selective inhibitors, rational combinations, and broad genomic screening. Moving forward, integrating kinase profiling with immune monitoring will further refine precision oncology, expanding durable benefit across diverse tumor types.
- 19 April 2026
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 36 (5) , 401-433
Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present)
1. The transforming growth factor β (TGF-β) superfamily comprises a large group of structurally related cytokines, including 33 members such as TGF-βs, bone morphogenetic proteins, growth and diffe...
- 19 April 2026
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 36 (5) , 401-433
Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present)
1. The transforming growth factor β (TGF-β) superfamily comprises a large group of structurally related cytokines, including 33 members such as TGF-βs, bone morphogenetic proteins, growth and diffe...
- 6 April 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1367
Design, synthesis, and biological evaluation of benzothiadiazolyl and benzoxadiazolyl derivatives as ALK5 inhibitors
- 6 April 2026
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1367
Design, synthesis, and biological evaluation of benzothiadiazolyl and benzoxadiazolyl derivatives as ALK5 inhibitors
- 12 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5067-5094
Synthetic strategies for small molecule compounds for the treatment of Parkinson’s disease: targeting α-synuclein
- 12 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5067-5094
Synthetic strategies for small molecule compounds for the treatment of Parkinson’s disease: targeting α-synuclein
- 14 January 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5575-5591
Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors
Six series of ether (14a–i and 15a–i), ester (17a–f and 18a–f) and amine derivatives (21a and 22a–g) containing quinoxalinyl and quinolinyl moieties were synthesized and evaluated for their inhibitory activities against activin receptor-like kinase 5 (ALK5). Among all the compounds, compound 22f (IC50 = 0.267 μM) exhibited the highest ALK5 inhibitory activity, comparable to that of the positive control LY-2157299. This study revealed that introducing amino groups into the side chains of quinoxalinyl and quinolinyl derivatives is more effective in enhancing ALK5 inhibition than ether or ester groups. These findings provide new insights and a theoretical foundation for the development of pyrazole-based ALK5 inhibitors.
- 14 January 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5575-5591
Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors
Six series of ether (14a–i and 15a–i), ester (17a–f and 18a–f) and amine derivatives (21a and 22a–g) containing quinoxalinyl and quinolinyl moieties were synthesized and evaluated for their inhibitory activities against activin receptor-like kinase 5 (ALK5). Among all the compounds, compound 22f (IC50 = 0.267 μM) exhibited the highest ALK5 inhibitory activity, comparable to that of the positive control LY-2157299. This study revealed that introducing amino groups into the side chains of quinoxalinyl and quinolinyl derivatives is more effective in enhancing ALK5 inhibition than ether or ester groups. These findings provide new insights and a theoretical foundation for the development of pyrazole-based ALK5 inhibitors.
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (11) , 2671-2682
Design and Synthesis of Betulinic Acid Derivatives as Antifibrotic Agents for Liver Fibrosis
Hepatic fibrosis is a major contributor to liver-related mortality and overall mortality. Currently, there is no established treatment for hepatic fibrosis. Research indicates that the transforming growth factor (TGF-β) signaling pathway is one of the key pathways involved in hepatic stellate cell (HSC) activation and fibrosis progression. Consequently, inhibiting the TGF-β signaling pathway represents a potential therapeutic strategy to combat hepatic fibrosis progression. Betulinic acid (BA) was widely extractable from natural plants, exhibits significant antifibrotic therapeutic effects. Three series of BA derivatives were synthesized and evaluated their antihepatic fibrosis activities. Most compounds showed no significant cytotoxicity in vitro. At nontoxic concentrations, these compounds effectively suppressed the TGF-β-induced upregulation of the liver fibrosis markers type I collagen and α-SMA. Notably, compound 3d dose-dependently inhibited extracellular matrix (ECM) deposition in TGF-treated HSCs and suppressed HSC activation. These findings indicate that compound 3d, acting as an antihepatic fibrosis agent, attenuates hepatic fibrosis by inhibiting the TGF-β signaling pathway.
- 3 November 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (11) , 2671-2682
Design and Synthesis of Betulinic Acid Derivatives as Antifibrotic Agents for Liver Fibrosis
Hepatic fibrosis is a major contributor to liver-related mortality and overall mortality. Currently, there is no established treatment for hepatic fibrosis. Research indicates that the transforming growth factor (TGF-β) signaling pathway is one of the key pathways involved in hepatic stellate cell (HSC) activation and fibrosis progression. Consequently, inhibiting the TGF-β signaling pathway represents a potential therapeutic strategy to combat hepatic fibrosis progression. Betulinic acid (BA) was widely extractable from natural plants, exhibits significant antifibrotic therapeutic effects. Three series of BA derivatives were synthesized and evaluated their antihepatic fibrosis activities. Most compounds showed no significant cytotoxicity in vitro. At nontoxic concentrations, these compounds effectively suppressed the TGF-β-induced upregulation of the liver fibrosis markers type I collagen and α-SMA. Notably, compound 3d dose-dependently inhibited extracellular matrix (ECM) deposition in TGF-treated HSCs and suppressed HSC activation. These findings indicate that compound 3d, acting as an antihepatic fibrosis agent, attenuates hepatic fibrosis by inhibiting the TGF-β signaling pathway.
- 25 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157192
2′,4′-dihydroxychalcone induces ferroptosis through ERO1A/GPX4 regulatory axis in cholangiocarcinoma
- 25 August 2025
- Published by Elsevier in Phytomedicine
- Vol. 147, 157192
2′,4′-dihydroxychalcone induces ferroptosis through ERO1A/GPX4 regulatory axis in cholangiocarcinoma
- 9 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 299, 118045
ALK5 kinase inhibitors in drug discovery: Structural insights and therapeutic applications
- 9 August 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 299, 118045
ALK5 kinase inhibitors in drug discovery: Structural insights and therapeutic applications
- 3 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 113997
Reactive oxygen species-responsive micelles targeting activated hepatic stellate cells for treating liver fibrosis
- 3 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 113997
Reactive oxygen species-responsive micelles targeting activated hepatic stellate cells for treating liver fibrosis